RNAC Q1 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-81.2% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$22M-1989.9% margin

Net Income

-$18M-1610.0% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

+244.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$409M

Total Liabilities

$431M

Stockholders' Equity

-$22M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$6M	-81.2%
Gross Profit	$1M	$6M	-81.2%
Operating Income	-$22M	-$13M	-64.0%
Net Income	-$18M	-$57M	+68.8%

Revenue Segments

Operating Segment

$1M100%